Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study.

Primary tabs

field_vote: 
Average: 10 (3 votes)
Publication type: 
Number of included patients: 
Therapeutic intervention: 
Therapeutic Substance(s): 

Evid Based Complement Alternat Med. 2011;2011:724743. Epub 2010 Dec 8.

Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study.

Chatterjee A, Biswas J, Chatterjee A, Bhattacharya S, Mukhopadhyay B, Mandal S.

Critical Cancer Management Research Centre & Clinic, 381 S K Deb Road, West Bengal, Kolkata 700 048, India.

Abstract

We prospectively studied the clinical efficacy of an alternative cancer treatment "Psorinum Therapy" in treating stomach, gall bladder, pancreatic and liver cancers. Our study was observational, open level and single arm. The participants' eligibility criteria included histopathology/cytopathology confirmation of malignancy, inoperable tumor, and no prior chemotherapy or radiation therapy. The primary outcome measures of the study were (i) to assess the radiological tumor response (ii) to find out how many participants survived at least 1 year, 2 years, 3 years, 4 years and finally 5 years after the beginning of the study considering each type of cancer. Psorinum-6x was administered orally to all the participants up to 0.02?ml/Kg body weight as a single dose in empty stomach per day for 2 years along with allopathic and homeopathic supportive cares. 158 participants (42 of stomach, 40 of gall bladder, 44 of pancreatic, 32 of liver) were included in the final analysis of the study. Complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases. Double-blind randomized controlled clinical trial should be conducted for further scientific exploration of this alternative cancer treatment.